Relevant bibliographies by topics / Adjuvant hormone therapy

Academic literature on the topic 'Adjuvant hormone therapy'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Adjuvant hormone therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Adjuvant hormone therapy"

1

Boyages, John, and Ken W. Tiver. "ADJUVANT SYSTEMIC THERAPY IN BREAST CANCER PART 1: ADJUVANT HORMONE THERAPY." ANZ Journal of Surgery 62, no. 5 (May 1992): 354–63. http://dx.doi.org/10.1111/j.1445-2197.1992.tb07203.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gupta, S., M. Singh, Amish Vora, G. Babu, M. Walia, V. Nautial, R. Saha, et al. "Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer." South Asian Journal of Cancer 07, no. 02 (April 2018): 142–45. http://dx.doi.org/10.4103/sajc.sajc_122_18.

Full text
Abstract:
AbstractOptimization of adjuvant systemic therapy in women with early-stage hormone receptor-positive breast cancer includes the consideration of chemotherapy and duration of hormone therapy. Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). Expert oncologist discussed on the duration of adjuvant hormonal therapy for improvement of OS and quality of life of breast cancer patients by providing reduction in recurrence and mortality. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.
APA, Harvard, Vancouver, ISO, and other styles
3

Latif, Asma, Alexander C. Small, Erin L. Moshier, Kerin B. Adelson, George Raptis, James H. Godbold, William K. Oh, and Matt D. Galsky. "Practice patterns in the use of adjuvant therapy for post-menopausal early-stage breast cancer in the pre- and post-Oncotype DX era." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e21032-e21032. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e21032.

Full text
Abstract:
e21032 Background: Personalized oncology offers the promise of selectively applying therapeutics to patients most likely to benefit, while sparing those unlikely to benefit from potentially toxic therapies. Oncotype DX is a 21-gene assay utilized to identify hormone-receptor positive (HR+), node negative, breast cancer (Br CA) patients who may be successfully treated with adjuvant hormonal therapy alone. We hypothesized that practice patterns with adjuvant therapy have changed since the commercial availability of Oncotype DX in 2004. Methods: The Public National Cancer Database was queried to identify patients age ≥ 50 with stage I or II Br CA diagnosed from 2000 to 2008. Patients were classified by adjuvant therapy including hormone, chemotherapy, hormone and chemotherapy, and no hormone or chemotherapy. Log-binomial regression was used to estimate prevalence ratios for the proportion of patients receiving adjuvant therapies from 2000-2003 compared to 2004-2008. Results: 833,018 patients age ≥ 50 with stage I or II Br CA were identified. The application of adjuvant therapies for the periods pre- and post-availability of Oncotype DX are detailed in the Table. Conclusions: There has been significant increase (13%) in the use of hormonal therapy alone as adjuvant therapy for patients age ≥ 50 with HR+ stage I-II Br CA since commercial availability of Oncotype DX. While this has been slightly offset by a decrease in the use of chemotherapy plus hormonal therapy, there has been a larger decrease in the use of “no adjuvant therapy”. Data regarding predictive biomarkers should be captured by registries in an effort to determine the true impact of these tests on treatment utilization. [Table: see text]
APA, Harvard, Vancouver, ISO, and other styles
4

Zeng, Erwei, Wei He, Jenny Bergqvist, and Kamila Czence. "Abstract P3-12-04: Extending therapy after 5-year adjuvant hormone therapy in breast cancer patients: A population-based study." Cancer Research 82, no. 4_Supplement (February 15, 2022): P3–12–04—P3–12–04. http://dx.doi.org/10.1158/1538-7445.sabcs21-p3-12-04.

Full text
Abstract:
Abstract Background: Clinical guidelines have recommended breast cancer patients with certain characteristics to extend their therapy after 5-year adjuvant hormone therapy. However, no study thus far has described the prevalence, predictors, and outcomes of extending adjuvant hormone therapy in the real world. Methods: We identified 2,937 breast cancer patients who completed 5-year adjuvant hormone therapy during 2010-2019 in Stockholm, Sweden, by linking the Quality Register for Breast Cancer, Prescribed Drug Register, and Cause-of-death Register. We followed them until September 2020. Extended adjuvant hormone therapy was defined as having at least 2 prescriptions of tamoxifen and/or aromatase inhibitors after completing 5-year therapy. We used logistic regression to examine predictors of extended adjuvant hormone therapy and Cox regression to examine whether extended therapy is associated with distant metastasis-free survival, disease-free survival and all-cause mortality. Results: The proportion of extending therapy after 5-year adjuvant hormone therapy increased by 7 times during the past decade, from 8.8% in 2010 to 63.7% in 2019. Predictors of extended adjuvant hormone therapy included young age (≤50 years) at extension, positive lymph node status, high tumor grade and chemotherapy, among which chemotherapy was the strongest predictors [adjusted hazard ratio (HR), 4.64 (95% CI, 3.64-5.92)]. Among patients with chemotherapy, extended therapy improved distant metastasis-free survival [adjusted HR, 0.34 (95 CI%, 0.15-0.78)] and disease-free survival [adjusted HR, 0.61 (95 CI%, 0.39-0.95)]. Therapy discontinuation rates were similar during the first and second five years. Conclusion: Increasing number of breast cancer patients are extending adjuvant hormone therapy, even among patients without clear recommendations in clinical guidelines. Our findings support extended adjuvant hormone therapy in breast cancer patients with chemotherapy. Citation Format: Erwei Zeng, Wei He, Jenny Bergqvist, Kamila Czence. Extending therapy after 5-year adjuvant hormone therapy in breast cancer patients: A population-based study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-12-04.
APA, Harvard, Vancouver, ISO, and other styles
5

Wiltshaw, E. "Adjuvant hormone therapy in ovarian cancer." Biomedicine & Pharmacotherapy 46, no. 4 (January 1992): 176. http://dx.doi.org/10.1016/0753-3322(92)90032-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Blomqvist, Carl P., Inkeri Elomaa, and Pentti Rissanen. "Adjuvant Hormone Therapy in Breast Cancer." Annals of Medicine 24, no. 2 (January 1992): 91–96. http://dx.doi.org/10.3109/07853899209148333.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kovalenko, E. I., I. B. Kononenko, A. V. Snegovoi, O. P. Grebennikova, and L. V. Manzyuk. "Adverse effects of adjuvant endocrine therapy." Medical Council, no. 10 (July 19, 2018): 64–69. http://dx.doi.org/10.21518/2079-701x-2018-10-64-69.

Full text
Abstract:
Hormonal therapy is a highly effective and well tolerable treatment of hormone-responsive breast cancer. However, it has some side effects that can affect quality of life and lead to treatment discontinuation. Common side effects of tamoxifen and aromatase inhibitors are discussed in this article: menopausal, gynecological symptoms, cardiovascular and musculoskeletal adverse events. Some of them are preventable and manageable. In order to maintain good quality of life during treatment the oncologists should pay more attention to the side effects that lead to it’s deterioration and not be too anxious about insignificant ones.
APA, Harvard, Vancouver, ISO, and other styles
8

Loibl, S., G. von Minckwitz, and M. Kaufmann. "Adjuvant hormone therapy following primary therapy for endometrial cancer." European Journal of Cancer 38 (September 2002): 41–43. http://dx.doi.org/10.1016/s0959-8049(02)00281-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Slonimskaya, E. M., A. V. Doroshenko, P. V. Kazantseva, N. A. Tarabanovskaya, and R. Yu Vernadsky. "Individual approach to choosing an appropriate regimen of adjuvant hormone therapy in patients with early-stage breast cancer." Tumors of female reproductive system 14, no. 3 (October 16, 2018): 48–54. http://dx.doi.org/10.17650/1994-4098-2018-14-3-48-54.

Full text
Abstract:
Adjuvant hormone therapy is considered the gold standard of therapy for hormone receptor-positive operable breast cancer. The approach to adjuvant hormone therapy in premenopausal patients has changed significantly in recent years. This change was caused by clinical trials, which have confirmed the advantage of adding ovarian suppression to tamoxifen or aromatase inhibitors monotherapy. Individual approach to choosing an appropriate regimen of adjuvant hormone therapy in premenopausal patients with breast cancer should be based on the assessment of risks for relapse, expected effectiveness of treatment and evaluation of drug safety.
APA, Harvard, Vancouver, ISO, and other styles
10

Cutolo, Maurizio. "SEX HORMONE ADJUVANT THERAPY IN RHEUMATOID ARTHRITIS." Rheumatic Disease Clinics of North America 26, no. 4 (November 2000): 881–95. http://dx.doi.org/10.1016/s0889-857x(05)70174-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Adjuvant hormone therapy"

1

He, Ru, and 何茹. "Effectiveness and toxicity of aromatase inhabitors [i.e. inhibitors] in adjuvant therapy for hormone receptor positive postmenopausalbreast cancer: a meta-analysis." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B46936026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wirth, Manfred, and Michael Fröhner. "A Review of Studies of Hormonal Adjuvant Therapy in Prostate Cancer." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-134738.

Full text
Abstract:
There is increasing interest in the use of adjuvant hormonal therapies, which are given after the resection or destruction of all gross disease, in early-stage prostate cancer, as a significant proportion of patients experience progression and/or die from the disease despite undergoing therapy with curative intent. Several retrospective studies suggest that adjuvant hormonal therapy may improve long-term outcome after radical surgery in men with positive lymph nodes, although this approach has yet to be studied in a prospective setting. No studies of adjuvant therapy for patients with extracapsular extension at surgery have been completed, but in an interim analysis of an open controlled trial, adjuvant flutamide significantly improved progression-free survival at 4 years. Three prospective studies in the radiotherapy setting have shown that adjuvant luteinizing hormone-releasing hormone (LH-RH) agonist therapy significantly improves progression-free and/or overall survival. Future studies need to define patient subgroups who will benefit most from adjuvant therapy. The side effects of the different therapeutic options also need to be compared. It is hoped that many of the outstanding questions concerning adjuvant hormonal therapy will be answered by the ongoing Bicalutamide Early Prostate Cancer Programme
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
APA, Harvard, Vancouver, ISO, and other styles
3

Wirth, Manfred, and Michael Fröhner. "A Review of Studies of Hormonal Adjuvant Therapy in Prostate Cancer." Karger, 1999. https://tud.qucosa.de/id/qucosa%3A27593.

Full text
Abstract:
There is increasing interest in the use of adjuvant hormonal therapies, which are given after the resection or destruction of all gross disease, in early-stage prostate cancer, as a significant proportion of patients experience progression and/or die from the disease despite undergoing therapy with curative intent. Several retrospective studies suggest that adjuvant hormonal therapy may improve long-term outcome after radical surgery in men with positive lymph nodes, although this approach has yet to be studied in a prospective setting. No studies of adjuvant therapy for patients with extracapsular extension at surgery have been completed, but in an interim analysis of an open controlled trial, adjuvant flutamide significantly improved progression-free survival at 4 years. Three prospective studies in the radiotherapy setting have shown that adjuvant luteinizing hormone-releasing hormone (LH-RH) agonist therapy significantly improves progression-free and/or overall survival. Future studies need to define patient subgroups who will benefit most from adjuvant therapy. The side effects of the different therapeutic options also need to be compared. It is hoped that many of the outstanding questions concerning adjuvant hormonal therapy will be answered by the ongoing Bicalutamide Early Prostate Cancer Programme.
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
APA, Harvard, Vancouver, ISO, and other styles
4

Chari, Venkatesh Vasu. "Drug Targets to Improve the Outcome of Hormonal Adjuvant Therapy in Breast and Prostate Cancers." University of Toledo Health Science Campus / OhioLINK, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=mco1384738922.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Salazar, Marcela d'Alincourt. "Genomic Effects of Hormonal Adjuvant Therapies that Could Support the Emergence of Drug Resistance in Breast Cancer." University of Toledo Health Science Campus / OhioLINK, 2010. http://rave.ohiolink.edu/etdc/view?acc_num=mco1280929084.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bhosle, Monali Jaysing. "Outcomes associated with adjuvant hormonal therapy: are they any differences between black and white women with primary breast cancer?" The Ohio State University, 2007. http://rave.ohiolink.edu/etdc/view?acc_num=osu1189093998.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bhosle, Monali Jaysing. "Outcomes associated with adjuvant hormonal therapy are there any differences between black and white women with primary breast cancer? /." Columbus, Ohio : Ohio State University, 2007. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1189093998.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

CHENG, WEN-HSUEN, and 鄭文雪. "The Experience of Adjuvant Hormonal Therapy in Women with Breast Cancer." Thesis, 2009. http://ndltd.ncl.edu.tw/handle/49832653497228692742.

Full text
Abstract:
碩士
國立台北護理學院
護理研究所
98
This study was conducted by the method of qualitative analysis of the data collected by in-depth interviews of the women with breast cancer who were taking adjuvant hormonal therapy. The qualitative analysis used constant comparative method for data collection and subsequent data analysis. The target population of this study were women with confirmed pathological diagnosis of breast cancer, regardless of whether she had received chemotherapy in the past; who’s currently receiving adjuvant oral hormonal therapy for at least six months, and was willing to share their experience by participating in this study. This study collected data from a total of 11 cases. The researcher was the data collector. The research tools involved the general information of each case and the open-ended interview guide. Participants decided where and when the interview took place. Data was collected by in-depth face to face interview and the content was recorded by a voice recorder. The average time for each interview was about 65 minutes. For insuring the validity of this study, the method developed by Lincoln and Guba (1985) was used to evaluate and confirm the credibility, transferability, dependability, and confirmability of the study. The results of this study covered three aspects of the experience of the breast cancer patients who received adjuvant hormonal therapy, which includes: the experience of coexistence with the medication, life style adjustment after taking the medication, and restructuring for the meaning of life. Hopefully, this study will raise the cognition of the medical staff for the the experience of adjuvant hormonal therapy in women with breast cancer and provide a comprehensive and holistic patient care.
APA, Harvard, Vancouver, ISO, and other styles
9

Huang, Chiung-Hsuan, and 黃瓊萱. "The Health Needs among Breast Cancer Women Receiving Adjuvant Hormonal Therapy." Thesis, 2007. http://ndltd.ncl.edu.tw/handle/10191090706627615785.

Full text
Abstract:
碩士
國立台北護理學院
護理研究所
95
Breast cancer patients undergoing adjuvant hormone therapy is increasing recently. The health needs of these patients have their specific health concerns, such as the management of their menopausal symptoms. However, little studies were conducted in Taiwan. The purposes of this study were to explore the health needs and related factors such as demographic data, health status and menopausal disturbance symptoms among breast cancer patients undergoing adjuvant hormone therapy in Taiwan. Sixty-five women were recruited. The collected data were analyzed through the statistical software, SPSS 14.0. The findings of this study were as follows: 1.The mean age of the women was 48.40. The average time of post-operation was 2.40 years. All women were undergoing the adjuvant hormone therapy. Average duration of using adjuvant hormone therapy was 1.89 years. 75% of the women have received chemotherapy and 47.69% of women have been treated by radiotherapy. 2.The satisfaction level of the holistic health needs was at the level of moderate to good. The order of satisfaction level of the health needs was: psychosocial support needs, information needs and physical needs. The top five issues of un-meted health needs were: “how to prevent from menopausal heart diseases”, “how to manage menopausal symptoms such as bone and joint, mental and vasomotor symptoms” and “How to use complimentary and alterative therapy to prevent from breast cancer recurrence”. Women expressed that they needed the knowledge of prevent from breast cancer recurrence and body discomforts such as insomnia, hot flash and joint pain during receiving hormone therapy. 3.Women reported that their health status were worse than before. Self-perceived health status was at moderate good level. The women perceived occasionally negative feelings. There is little influences on daily activity except the exertion of cleaning, wiping the floor, carrying heavy bag. The women expressed that their menopausal disturbance symptoms were at ‘mild’ disturbcance level. The rank of menopausal disturbances symptoms was: sleep disturbance, difficulty in falling asleep, forgetfulness, insufficient sleep and irregular menses. 4.The satisfactions of the holistic health needs were positively related with the time of using hormone therapy, self-perceived mental health status and menopausal disturbance symptoms and negatively related with menopausal disturbance symptoms. 5.The mental health status, reproductive menopausal symptoms and time of using adjuvant hormone therapy explained 47.5% of the variance of the satisfaction of holistic health needs. This study suggests health providers to provide active support and information to breast cancer women about possible menopausal symptoms and how to prevent from the recurrence of breast cancer including self-examination of recurrence symptoms, complimentary and alterative therapy.
APA, Harvard, Vancouver, ISO, and other styles
10

SU, CHIU-PING, and 蘇秋萍. "Relation of cognitive function and functional health status in women receiving adjuvant hormonal therapy." Thesis, 2010. http://ndltd.ncl.edu.tw/handle/72568682976163617258.

Full text
Abstract:
碩士
國立台北護理學院
護理研究所
98
The adjuvant hormonal therapy is one of common treatments for breast cancer. The women with breast cancer often complained about memory loss and attention deficit after cancer treatment. There is limited information about the cognitive function and its relation with functional health. Thus, the purpose of this study was to describe relation of cognitive function and functional status in women receiving adjuvant hormonal therapy. This was a cross-section, descriptive study. A conveniences sample of 129 women with early-stage breast cancer was recruited in a medical center in Taipei. Cognitive function was measured by Montreal Cognitive Assessment (MoCA) to test the visuospatial, memory, attention, language, abstraction and orientation, and by EORTC-CF for perceived cognitive difficulty.. Functional health was measured by SF-36. All three instruments were in Traditional Chinese and demonstrated Cronbach’s α of 0.70 – 0.82. Data were analyzed by using SPSS 16.0. The women had a mean age of 52.2 and were 2.5 since diagnosis. A majority of them were married, with high-school-or-above education and had stage II breast cancer (56.6%), MRM (53.5%), chemotherapy (74.4%) and Tamoxifen (75.2%). Results showed that the women reported a mild to moderate cognitive difficulty (67.5±21.4); 41.9% of them performed less than 26 on MoCA after adjusted with education; and 24% were compatible with mild cognitive deficit and greater than 1/4 can’t perform visualspatial. After control with chronic illness, the visualspatial, memory, abstraction and EORTC-CF were significantly related to the role limitations due to physical function.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Adjuvant hormone therapy"

1

1944-, Miller William R., and Ingle James N. 1944-, eds. Endocrine therapy in breast cancer. New York: Marcel Dekker, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Targeted and biological therapies. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0009.

Full text
Abstract:
Hormone therapy describes the role of hormones in the growth of a variety of cancers, and the therapeutic effects of manipulation of hormone levels in these diseases. Sex hormones stimulate the growth of breast and prostate cancers, many of which respond to surgical removal of the hormone-secreting gonad. Pharmacological measures to deliver hormone therapy in these diseases include luteinising hormone releasing hormone (LHRH) agonists and antagonists, inhibitors of sex hormone synthesis, and inhibitors of hormone-receptor binding. These treatments have established benefits in both in the control of advanced disease and the adjuvant therapy of early-stage disease. The pros and cons of combination hormone therapy are discussed. Resistance to hormone therapy may be primary or acquired, and the likely mechanisms are described.
APA, Harvard, Vancouver, ISO, and other styles
3

(Editor), W. Jonat, M. Kaufmann (Editor), and K. Munk (Editor), eds. Hormone-Dependent Tumors: Basic Research and Clinical Studies : 9th International Expert Meeting of the Dr. Mildred Scheel Stiftung Fur Krebsforschung, ... 19 (Contributions to Oncology, Vol 50). S. Karger AG (Switzerland), 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff, and Madhumita Bhattacharyya. Gynaecological cancers. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0020_update_001.

Full text
Abstract:
Genitourinary cancers examines the malignancies arising in the kidney, ureter, bladder, prostate, testis, and penis. Renal cancer has high propensity for systemic spread, largely mediated by overexpression of vascular endothelial growth factor (VEGF). Treatments include surgery, immunotherapy, and targeted therapy. Wilms tumour, a childhood malignancy of the kidney, warrants specialist paediatric oncology management to provide expertise in its unique pathology, staging, and treatment, often with surgery and chemotherapy. Cancer of the bladder and ureters, another tobacco related cancer, may present as either superficial or invasive disease. The former is managed by transurethral resection and intravesical therapy. The latter may require radical surgery, preoperative chemotherapy, or radiotherapy. Prostate cancer, the commonest male cancer, is an androgen dependent malignancy. It has attracted controversy with regards to PSA screening, and potential over treatment with radical prostatectomy. Division into low, intermediate, and high risk disease according to tumour grade, stage, and PSA helps in deciding best treatment, antiandrogen therapy for metastatic disease, radiotherapy and adjuvant hormone therapy for locally advanced disease, either surgery or radiotherapy for early intermediate risk disease, and active monitoring for low risk cases. Testicular cancer divides according to pathology into seminoma, nonseminomatous germ cell tumours (NSGCT), and mixed tumours, the latter two frequently producing tumour markers, alpha-fetoprotein (AFP) and/or human chorionic gonadotrophin (HCG). Stage I disease is managed by inguinal orchidectomy and surveillance or adjuvant chemotherapy. More advanced disease is managed by chemotherapy, with high probability of cure in the majority. Penile cancer, often HPV related, can be excised when it presents early, but delay in presentation may lead to regional and systemic spread with poor prognosis.
APA, Harvard, Vancouver, ISO, and other styles
5

Kulkarni, Kunal, James Harrison, Mohamed Baguneid, and Bernard Prendergast, eds. Breast surgery. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198729426.003.0021.

Full text
Abstract:
Breast cancer trials started in the 1930s and have made major contributions to the field of evidence-based medicine and the management of breast cancer. In the United States, the National Surgical and Adjuvant Breast Project (NSABP), established in 1957, has been responsible for many pivotal breast cancer trials in breast cancer surgery, radiotherapy, chemotherapy, and hormone therapy. The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) started in 1985, with the aim of sharing data from high-quality randomized trials worldwide to promote high-quality meta-analyses. Increasingly, breast cancer is being recognized not as one single pathology, but as a disease with a biology and behaviour that is individual to each patient. This chapter discusses trials which have been pivotal in this dynamic time for breast cancer research and which have led the way in personalized therapies for cancer patients.
APA, Harvard, Vancouver, ISO, and other styles
6

Cavalli, Franco, ed. Endocrine Therapy Of Breast Cancer (ENDOCRINE THERAPY OF BREAST CANCER). Springer, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Francesco, Cavalli, ed. Endocrine therapy of breast cancer III. Berlin: Springer-Verlag, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

MIller/Ingle. Endocrine Therapy in Breast Cancer. Informa Healthcare, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

(Editor), James N. Ingle, and Mitchell Dowsett (Editor), eds. Endocrine Therapy for Breast Cancer. Informa Healthcare, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Adjuvant hormone therapy"

1

Pritchard, K. I., J. A. Roy, and C. A. Sawka. "Sex Hormones and Breast Cancer: The Issue of Hormone Replacement." In Adjuvant Therapy of Breast Cancer V, 285–93. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-79278-6_32.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Shimada, Andrea K., João Victor Machado Alessi, Bruna Zucchetti, and Artur Katz. "Adjuvant Hormone Therapy for Breast Cancer." In Breast Diseases, 479–87. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-13636-9_58.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kreuser, E. D., W. D. Hetzel, F. Porzsolt, and R. Hautmann. "Reproductive Toxicity with and Without Administration of Luteinizing-Hormone-Releasing Hormone Agonist During Adjuvant Chemotherapy in Patients with Germ Cell Tumors." In Cancer Therapy, 292–302. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-73721-3_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Boccardo, F., A. Rubagotti, D. Amoroso, M. Mesiti, P. Pacini, L. Gallo, P. Sismondi, et al. "Italian Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group Trials." In Recent Results in Cancer Research, 453–70. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-45769-2_44.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bolla, M., Th M. de Reijke, A. Zurlo, and L. Collette. "Adjuvant Hormone Therapy in Locally Advanced and Localized Prostate Cancer: Three EORTC Trials." In Controversies in Uro-Oncology, 81–86. Basel: KARGER, 2002. http://dx.doi.org/10.1159/000061332.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Abdi, E. A., H. Jenkins, and C. May. "Relationship of Breast Cancer Hormone Receptors, Menopausal Status, and Adjuvant Therapy to Site(s) of Recurrence and Survival." In Fundamental Problems in Breast Cancer, 177–85. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-2049-4_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Thakar, Alok. "Adjuvant Chemotherapy and Hormonal Therapy." In Juvenile Angiofibroma, 243–50. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-45343-9_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gradishar, William J. "Adjuvant Therapy for Breast Cancer: Hormonal Therapy." In Breast Disease, 353–62. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1145-5_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zelnak, Amelia B., and Ruth M. O'Regan. "Adjuvant Hormonal Therapy for Early-Stage Breast Cancer." In Cancer Treatment and Research, 63–78. Boston, MA: Springer US, 2008. http://dx.doi.org/10.1007/978-0-387-73161-2_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wirth, Manfred P., Oliver W. Hakenberg, and Michael Froehner. "Adjuvant Hormonal Treatment – The Bicalutamide Early Prostate Cancer Program." In Frontiers of Radiation Therapy and Oncology, 39–48. Basel: KARGER, 2008. http://dx.doi.org/10.1159/000139877.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Adjuvant hormone therapy"

1

Chagpar, AB, JL Lewis, KM McMasters, and MJ Edwards. "Factors influencing the decision to add chemotherapy to adjuvant hormonal therapy in women with hormone receptor-positive breast cancer." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-4105.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Felder, Tisha M., Lincy S. Lal, Dana Stafkey-Mailey, Phoenix Do, Kevin Lu, and Charles L. Bennett. "Abstract A52: Receipt of adjuvant hormonal therapy among Medicaid enrollees diagnosed with hormone-receptor positive breast cancer, 2004-2007." In Abstracts: Fifth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Oct 27–30, 2012; San Diego, CA. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1055-9965.disp12-a52.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lohrisch, C., C. Speers, S. Chia, H. Kennecke, S. Ellard, and S. Tyldesley. "Abstract P1-13-01: Risk of recurrence following 5 years of adjuvant hormone therapy for hormone receptor positive early breast cancer." In Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/0008-5472.sabcs13-p1-13-01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Suh, Christina H., Sumita Bhatta, Ningqi Hou, Zakiya N. Moton, and Susan Hong. "Abstract A31: Factors associated with compliance to adjuvant hormone therapy for African American and Caucasian women." In Abstracts: Fifth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Oct 27–30, 2012; San Diego, CA. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1055-9965.disp12-a31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Blok, EJ, A. Charehbili, JR Kroep, CM Seynaeve, CJH van de Velde, and PJK Kuppen. "Abstract P6-01-05: Radiological evaluation of neo-adjuvant endocrine therapy in hormone-receptor positive early breast cancer." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-p6-01-05.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kim, Jongjin, Wonshik Han, Hyeong-Gon Moon, Min Kyoon Kim, Eunshin Lee, Tae-Kyung Yoo, Han-Byoel Lee, et al. "Abstract P1-12-13: Factors associated with adherence to adjuvant endocrine therapy in patients with hormone receptor positive breast cancer." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p1-12-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mayer, EL, AM DeMichele, H. Guo, KD Miller, HS Rugo, B. Schneider, AG Waks, et al. "Abstract PD5-06: Adjuvant palbociclib plus endocrine therapy for hormone receptor positive/HER2 negative breast cancer: A phase II feasibility study." In Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.sabcs17-pd5-06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hou, Ningqi, Katharine Yao, David J. Winchester, Nora Jaskowiak, David P. Winchester, and Dezheng Huo. "Abstract A62: Secular trends and disparity of adjuvant hormone therapy use for ductal carcinoma in situ: National Cancer Database, 1998–2007." In Abstracts: AACR International Conference on the Science of Cancer Health Disparities‐‐ Sep 18-Sep 21, 2011; Washington, DC. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1055-9965.disp-11-a62.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

He, W., LE Bergman, S. Törnberg, F. Strand, P. Hall, and K. Czene. "Abstract P6-08-20: Non-adherers of mammography screening: Delayed surgery, early discontinuation of adjuvant hormone therapy, and worse breast cancer outcomes." In Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.sabcs17-p6-08-20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tokunaga, E., S. Akiyoshi, C. Koga, Y. Nakamura, K. Taguchi, M. Ishida, and S. Ohno. "Abstract P5-08-47: Clinical outcome of pathological T1N0 breast cancer according to the hormone receptor and HER2 status and adjuvant therapy." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-p5-08-47.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Adjuvant hormone therapy"

1

Zhang, Meilin, Jian Song, Hongguang Yang, Feng Jin, and Ang Zheng. Adjuvant and neoadjuvant therapy of cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative, early breast cancer: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.11.0008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Adjuvant hormone therapy' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography